Evidence map›Paper›PMID 28323055›Full record

ArticlePulmonary pharmacology & therapeutics2017

A 6-alkylsalicylate histone acetyltransferase inhibitor inhibits histone acetylation and pro-inflammatory gene expression in murine precision-cut lung slices.

Thea van den Bosch, Niek G J Leus, Hannah Wapenaar, Alexander Boichenko, Jos Hermans, Rainer Bischoff, Hidde J Haisma, Frank J Dekker

Open access · bronzeAbstract read
In one paragraph

Article in Pulmonary pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Organotypic Models of Lung Cancer.Current topics in microbiology and immunology · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Thea van den BoschChemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands.
Niek G J LeusChemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands.
Hannah WapenaarChemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands.
Alexander BoichenkoAnalytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands.
Jos HermansAnalytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands.
Rainer BischoffAnalytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands.
Hidde J HaismaChemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands.
Frank J DekkerChemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands. Electronic address: f.j.dekker@rug.nl.
University of Groningen · NL

Funding

European Research Council 309782
6 · The paper itself

Abstract

Lysine acetylations are post-translational modifications of cellular proteins, that are crucial in the regulation of many cellular processes. Lysine acetylations on histone proteins are part of the epigenetic code regulating gene expression and are installed by histone acetyltransferases. Observations that inflammatory lung diseases, such as asthma and chronic obstructive pulmonary disease, are characterized by increased histone acetyltransferase activity indicate that development of small molecule inhibitors for these enzymes might be a valuable approach towards new therapies for these diseases. The 6-alkylsalicylate MG149 is a candidate to explore this hypothesis because it has been demonstrated to inhibit the MYST type histone acetyltransferases. In this study, we determined the K

Indexed as

AnimalsBibenzylsChromatography, LiquidGene Expression RegulationHistone AcetyltransferasesHistone Deacetylase InhibitorsHistone DeacetylasesLungMiceSalicylatesTandem Mass Spectrometry2-(2-(4-heptylphenyl)ethyl)-6-hydroxy-benzoic acidBibenzylsHistone AcetyltransferasesHistone Deacetylase InhibitorsHistone DeacetylasesSalicylates6-AlkylsalicylateAcetylationAcetyltransferase inhibitorInflammationLungMG149MG149 (PubChem CID: 49864204)SAHA (PubChem CID: 5311)

Identifiers

PMID28323055
PMCPMC5447808
OpenAlexW2596411872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.